BMO Capital Reiterates Buy Rating for Taysha Gene Therapies

On June 23, 2026, BMO Capital reiterated its buy rating for Taysha Gene Therapies, Inc. (NASDAQ: TSHA), setting a price target of $14. This reflects continued confidence in the biotechnology company's potential.

Other Institutional Activity in Taysha Gene Therapies

RA Capital Management, L.P. held steady with 23.56 million shares valued at about $105.3 million. Goldman Sachs Group Inc. increased its holdings by 8.68 million shares, bringing its total to 22.37 million shares worth approximately $99.99 million, marking a 63.4% increase. Avoro Capital Advisors LLC maintained its position with 21.7 million shares valued at $96.99 million. BlackRock, Inc. trimmed its stake by 277,521 shares to 18.37 million shares valued at $82.09 million, a 1.5% decrease. Vestal Point Capital, LP boosted its holdings by 4.25 million shares, ending with 18 million shares worth about $80.46 million, a 30.9% increase.

Taysha Gene Therapies, Inc. Stock Up 7.6%

Shares of NasdaqGS:TSHA traded near $6.53 on Tuesday. Taysha Gene Therapies has a market cap of around $1.88 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock has a 52-week low of $2.25 and a high of $7.30, with a 50-day moving average of $5.96 and a 200-day moving average of $4.88. The company has a strong current ratio of 14.04 and a quick ratio of 13.76, indicating good liquidity, with a debt-to-equity ratio of 32.34.

Recent Earnings

Taysha Gene Therapies reported revenue of $7.47 million in its latest quarterly earnings. However, the company is not yet profitable, with an EPS of -$0.38 and a return on equity of -97.28%. The net margin stands at 0.0%. The next earnings release is scheduled for August 12, 2026.

Insider Buying and Selling at Taysha Gene Therapies, Inc.

On June 1, 2026, several insiders made notable purchases. John Stalfort III acquired 42,671 shares, while Alison Long and Laura Sepp-Lorenzino each bought the same amount. Additionally, Laura Sepp-Lorenzino and John Stalfort III also purchased 21,335 shares each. Phillip Donenberg also acquired 21,335 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 23, 2026, BMO Capital maintained its buy rating with a $14 price target. B of A Securities and Citizens also maintained buy ratings, setting targets at $10 and $11, respectively. Needham reiterated a buy rating with a $12 target on June 22, 2026. The consensus among analysts is a strong buy, with an average target price of $12.23 based on 13 opinions.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., based in Dallas, Texas, is a biotechnology company focused on developing gene therapies for severe genetic diseases of the central nervous system. The company's pipeline includes treatments for conditions like giant axonal neuropathy and Rett syndrome. Led by CEO Sean P. Nolan, Taysha collaborates with The University of Texas Southwestern Medical Center to advance its research.

Bottom Line

BMO Capital's reiterated buy rating and $14 target for Taysha Gene Therapies highlight ongoing confidence in the company's prospects. Investors closely track such updates, though it's important to remember that analyst ratings are based on past data and may not reflect current market conditions. The company's financial health and pipeline developments will be key factors for future performance.